Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Lennar Corporation (LEN) Price & Performance

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

Lennar (LEN) trades at $73.53, down 1.5% on the day, with a bearish technical signal and recent earnings misses. The homebuilder shows declining revenue and profit margins, with 2025 revenue at $34.19B and net income of $2.08B. Valuation metrics appear attractive with P/E of 14.19 and P/B of 0.83, but cash flow trends show negative net cash flow of -$1.16B in 2025. Berkshire Hathaway has been accumulating shares, building an 11.2% stake as of October 2026.

Lennar presents a value opportunity with below-book valuation and strong institutional interest, but faces headwinds from declining profitability, negative cash flow, and housing market challenges. The stock trades below the $77.38 consensus price target, offering potential upside if operational improvements materialize, though execution risks and macroeconomic pressures remain concerns.